


There is no page 3  
Only 2 pages on the

FORM PTO-1449  
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Sheet 1 of 2

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
AM						<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

N.P.	AR	Neurath, et al., "Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit NF- $\kappa$ B abrogates established experimental colitis in mice", Nature Med., Vol. 2 (9), pp. 998-1004 (1996)
M.R.	AS	Marok, et al., "Activation of the Transcription Factor Nuclear Factor- $\kappa$ B In Human Inflame Synovial Tissue", Arthritis & Rheum., Vol. 39 (4), pp. 583-591 (1996)
R.R.	AT	Cabannes, et al., "Mutations in the $I\kappa Ba$ gene in Hodgkin's disease suggest a tumour suppressor role for $I\kappa Ba$ , Oncogene, Vol. 18, pp. 3063-3070 (1999)

EXAMINER *M. Moashy*

DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Sheet 2 of 82

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

Ref.	2AA	Rayet, et al., "Aberrant <i>rel/nfkb</i> genes and activity in human cancer", <i>Oncogene</i> , Vol. 18, pp. 6938-6947 (1999)
Ref.	2AB	Brown, et al., "Control of IκB-α Proteolysis by Site-Specific, Signal-Induced Phosphorylation", Vol. 267, pp. 1485-1488 (1995)
Ref.	2AC	Hiscott, et al., "Hostile takeovers: viral appropriation of the NF-κB pathway", Vol. 107 (2), pp. 143-151 (2001)
Ref.	2AD	Yamamoto, et al., "Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer", <i>J. Clin. Inves.</i> , Vol. 107 (2), pp. 135-142 (2001)
Ref.	2AE	Magkoff, et al., "NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint", <i>Proc. Natl. Acad. Sci.</i> , Vol. 95, pp. 13859-13864 (1998) USA
Ref.	2AF	Bondeson, et al., "Defining therapeutic targets by using adenovirus: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators", <i>Proc. Natl. Acad. Sci.</i> , Vol. 96, pp. 5668-5673, (1999)
Ref.	2AG	Christman, et al., "The Role of Nuclear Factor -κ B in Pulmonary Diseases", <i>Chest</i> , Vol. 117, pp. 1482-1487 (2000)
Ref.	2AH	Baldwin, Albert S., Jr., "The NF-κB and IκB Proteins: New Discoveries and Insights", <i>Annu. Rev. Immunol.</i> , Vol. 14, pp. 649-681 (1996)
	2AI	Smahl, et al., "Genomic rearrangement in NEMO impairs NF-κB activation and is a cause of incontinentia pigmenti", <i>Nature</i> , Vol. 405, pp. 466-472 (2000)
Ref.	2AJ	Whiteside, et al., "I kappa B epsilon, a novel member of the IκB family, controls RelA and cRel NF-κB activity," <i>EMBO J.</i> , Vol. 16 (6), pp. 1413-1426 (1997)
Ref.	2AK	Jain, et al., "Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohidrotic ectodermal dysplasia", <i>Nature immunol.</i> , Vol. 2 (3), pp. 223-228 (2001)
Ref.	2AL	Doffinger, et al., "X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling", <i>Nature Genetics</i> , Vol. 27, pp. 277-285 (2001)
Ref.	2AM	Baeuerle, et al., "NF-κB: Ten Years After", <i>Cell</i> , Vol. 87, pp. 13-20 (1996)
Ref.	2AN	Siebenlist, et al., Structure, Regulation and Function of NF-κB", <i>Cell. Biol.</i> , Vol. 10, pp. 405-455 (1994)

EXAMINER

H. Monshir

DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Sheet 1 of 1

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 16503

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
AM						<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

RE. RE.	AR	NCBI Entrez Accession No. BC013899 (gi:15530235), Strausberg, R., September 10, 2001
RE. RE.	AS	NCBI Entrez Accession No. BC013899 (gi:33872964), Strausberg, et al., June 29, 2004
RE. RE.	AT	Mammalian Gene Collection Program Team, "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences", PNAS, Vol. 99 (26), pp. 16899-16903 (2002)

## EXAMINER

Reibanshi

## DATE CONSIDERED

4/27/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Sheet 1 of 1

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM						<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

RE-RE.	AR	NCBI Entrez Accession No. BC013899 (gi:15530235), Strausberg, R., September 10, 2001
RE-RE.	AS	NCBI Entrez Accession No. BC013899 (gi:33872964), Strausberg, et al., June 29, 2004
RE-RE.	AT	Mammalian Gene Collection Program Team, "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences", PNAS, Vol. 99 (26), pp. 16899-16903 (2002)

EXAMINER	<i>Reikibashi</i>	DATE CONSIDERED	<i>4/18/06</i>
----------	-------------------	-----------------	----------------

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653



Use several sheets if necessary)

MAR 20 2006

## U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
M.M.	AA	10/308,279	12/3/02	Carman, et al.			

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
	AM						<input type="checkbox"/> <input type="checkbox"/>
	AN						<input type="checkbox"/> <input type="checkbox"/>
	AO						<input type="checkbox"/> <input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

M.M.	AP	Ahmad, et al., "Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain", Molec. Cell, Vol. 12, pp. 1551-1564 (2003)
R.R.	AQ	Albagli-Curiel, et al., "Ambivalent role of BCL6 in cell survival and transformation", Oncogene, Vol. 22, pp. 507-516(2003)
R.R.	AR	Arima, et al., "A Putative Silencer Element in the IL-5 Gene Recognized by Bc16", J. Immunol., Vol. 169, pp. 829-836 (2002)

## EXAMINER

M. Moashy

## DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

RE-RE	2AA	Baron, et al., "The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis", PNAS, Vol. 99(5), pp. 2860-2865 (2002)
M.RE	2AB	Bellido, et al., "Bcl-6 and p53 mutations in lymphomas carrying the bcl-2/jh rearrangement", Haematologica, Vol. 87, pp. 908-917 (2002)
RE-RE	2AC	Bos, et al., "Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D <sub>1</sub> and hypoxia-inducible factor-1 $\alpha$ (HIF-1 $\alpha$ )", Oncogene, Vol. 22, pp. 8948-8951 (2003)
RE-RE	2AD	Brown, et al., "Control of I $\kappa$ B- $\alpha$ Proteolysis by Site-Specific, Signal-Induced Phosphorylation", Science, Vol. 267, pp. 1485-1488 (1995)
RE-RE	2AE	Burke, et al., "BMS-345541 Is a Highly Selective Inhibitor of I $\kappa$ B Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF- $\kappa$ B-dependent Transcription in Mice", J. Biol. Chem., Vol. 278(3), pp. 1450-1456 (2003)
RE-RE	2AF	Cattoretti, et al., "BCL-6 Protein Is Expressed in Germinal-Center B Cells", Blood, Vol. 86(1), pp. 45-53 (1995)
RE-RE	2AG	Chang, et. al., "Expression of p53, c-Myc, or Bcl-6 Suggests a Poor Prognosis in Primary Central Nervous System Diffuse Large B-Cell Lymphoma Among Immunocompetent Individuals", Arch. Pathol. Lab. Med., Vol. 127, pp. 208-212 (2003)
RE-RE	2AH	Chang, et al., "BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor", PNAS, USA, Vol. 93, pp. 6947-6952 (1996)
RE-RE	2AI	Davies, et al., "Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene", Oncogene, Vol. 18, pp. 365-375 (1999)
RE-RE	2AJ	Mattos, et al., "FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism", Molec. Cell. Biol., Vol. 24(22), pp. 10058-10071 (2004)
RE-RE	2AK	Dent, et al., "Control of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6", Science, Vol. 276, pp. 589-592 (1997)
RE-RE	2AL	Deregibus, et al., "HIV-1-Tat Protein Activates Phosphatidylinositol 3-Kinase/AKT-dependent Survival Pathways in Kaposi's Sarcoma Cells", J. Biol. Chem., Vol. 277(28), pp. 25195-25202 (2002)
RE-RE	2AM	Dhordain, et al., "Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein", PNAS, Vol. 94, pp. 10762-10767 (1997)
RE-RE	2AN	Flenghi, et al., "A Specific Monoclonal Antibody (PG-B6) Detects Expression of the BCL-6 Protein in Germinal Center B Cells", Amer. J. Pathol., Vol. 147(2), pp. 405-411 (1995)

EXAMINER

RE-Hoshi

DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

RE-RE	3AA	Gupta, et al., "Lineage-specific Modulation of Interleukin 4 Signaling by Interferon Regulatory Factor 4", J. Exp. Med., Vol. 190(12), pp. 1837-1848 (1999)
RE-RE	3AB	Hallermann, et al., "Molecular Cytogenetic Analysis of Chromosomal Breakpoints in the IGH, MYC, BCL6, and MALT1 Gene Loci in Primary Cutaneous B-cell Lymphomas", J. Invest. Dermatol., Vol. 123, pp. 213-219 (2004)
RE-RE	3AC	Hiscott, et al., "Hostile takeovers: viral appropriation of the NF- $\kappa$ B pathway", J. Clin. Invest., Vol. 107(2), pp. 143-151 (2001)
RE-RE	3AD	Hofmann, et al., "The Promoter Context Determines Mutual Repression or Synergism between NF- $\kappa$ B and the Glucocorticoid Receptor", Biol. Chem., Vol. 383, pp. 1947-1951 (2002)
RE-RE	3AE	Holton, et al., "A simple and efficient method for direct cloning of PCR products using ddT-tailed vectors", Nucleic Acids Res., Vol. 19(5), pp. 1156 (1990)
	3AF	Johnson, et al., "A Simple, Rapid Technique for Precise Mapping of Multiple Sequences in Two Colors Using a Single Optical Filter Set", GATA, Vol. 8(2), pp. 75-76 (1991)
RE-RE	3AG	Huynh, et al., "BC0R, a novel corepressor involved in BCL-6 repression", Genes Devel., Vol. 14, pp. 1810-1823 (2000)
RE-RE	3AH	Jardin, et al., "Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma", Blood, Vol. 102, pp. 1872-1876 (2003)
RE-RE	3AI	Jardin, et al., "Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma", Leukemia, Vol. 19, pp. 1824-1830 (2005)
RE-RE	3AJ	Johnson, et al., "A Simple, Rapid Technique for Precise Mapping of Multiple Sequences in Two Colors Using a Single Optical Filter Set", GATA, Vol. 8(2), pp. 75-76 (1991)
RE-RE	3AK	Johnson, et al., "Molecular Cloning of a Novel Human cdc2/CDC28-like Protein Kinase", J. Biol. Chem., Vol. 266(6), pp. 3402-3407 (1991)
RE-RE	3AL	Kanazawa, et al., "Expression of bcl-6 protein in normal skin and epidermal neoplasms", Path. Internat., Vol. 47, pp. 600-607 (1997)
RE-RE	3AM	Katzenberger, et al., "Cytogenetic Alterations Affecting BCL6 Are Predominantly Found in Follicular Lymphomas Grade 3B with a Diffuse Large B-Cell Component", Amer. J. Pathol., Vol. 165(2), pp. 481-490 (2004)
RE-RE	3AN	Kerckaert, et al., "LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas", Nature Genetics, Vol. 5, pp. 66-70 (1993)

EXAMINER

RE-Morchi

DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

RE-RE	4AA	Kurosu, et al., "BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells", Oncogene, Vol. 22, pp. 4459-4468 (2003)
RE-RE	4AB	Lee, et al., "POZ Domain Transcription Factor, FBI-1, Represses Transcription of ADH5/FDH by Interacting with the Zinc Finger and Interfering with DNA Binding Activity of SP1", J. Biol. Chem., Vol. 277(30), pp. 26761-26768 (2002)
RE-RE	4AC	Lemercier, et al., "Class II Histone Deacetylases Are Directly Recruited by BCL6 Transcriptional Repressor", J. Biol. Chem., Vol. 277(24), pp. 22045-22052 (2002)
RE-RE	4AD	Li, et al., "BCL-6 Negatively Regulates Expression of the NF-κB1 p105/p50 Subunit", J. Immunol., Vol. 174, pp. 205-214 (2005)
RE-RE	4AE	Lin, et al., "The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium", Urol. Res., Vol. 31, pp. 272-275 (2003)
RE-RE	4AF	Lossos, et al., "The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene", Leukemia, Vol. 17, pp. 1390-1397 (2003)
RE-RE	4AG	Migliazza, et al., "Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma", PNAS, Vol. 92, pp. 12520-12524 (1995) USA
RE-RE	4AH	Miki, et al., "Molecular Cloning of the Breakpoint for 3q27 Translocation in B-Cell Lymphomas and Leukemias", Blood, Vol. 83(1), pp. 217-222 (1994)
RE-RE	4AI	Miki, et al., "Gene Involved in the 3q27 Translocation Associated With B-Cell Lymphoma, BCL5, Encodes a Krüppel-Like Zinc-Finger Protein", Blood, Vol. 83(1), pp. 26-32 (1994)
RE-RE	4AJ	Min, et al., "Point mutation of 5' noncoding region of BCL-6 gene in primary gastric lymphomas", World J. Gastroenterol, Vol. 11(1), pp. 51-55 (2005)
RE-RE	4AK	Montesinos-Rongen, et al., "Molecular Characterization of BCL6 Breakpoints in Primary Diffuse Large B-cell Lymphomas of the Central Nervous System Identifies GAPD as Novel Translocation Partner", Brain Pathol., Vol. 13, pp. 534-538 (2003)
RE-RE	4AL	Niu, Hufeng, "The Proto-Oncogene BCL-6 In Normal And Malignant B Cell Development", Hematology Oncology, Vol. 20, pp. 155-166 (2002)
RE-RE	4AM	Niu, et al., "BCL6 Controls the Expression of the B7-1/CD80 Costimulatory Receptor in Germinal Center B Cells", J. Exp. Med., Vol. 198(2), pp. 211-221 (2003)
RE-RE	4AN	Ohno, H., "Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin's lymphoma", Histol Histopathol., Vol. 19, pp. 637-650 (2004)

EXAMINER

RE-PROASHI

DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

RE	SAA	Onizuka, et al., "BCL-6 Gene Product, a 92- to 98-kD Nuclear Phosphoprotein, Is Highly Expressed in Germinal Center B Cells and Their Neoplastic Counterparts", Blood, Vol. 86(1), pp. 28-37 (1995)
RE	SAB	Pasqualucci, et al., "Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6", Leukemia & Lymphoma, Vol. 44, Suppl. 3, pp. S5-S12 (2003)
RE	SAC	Pasqualucci, et al., "Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma", Blood, Vol. 101(8), pp. 2914-2923 (2003)
RE	SAD	Petrie, et al., "The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms", J. Biol. Chem., Vol. 278(18), pp. 16059-16072 (2003)
RE	SAE	Phan, et al., "The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells", Nature, Vol. 432, pp. 635-639 (2004)
RE	SAF	Pileri, et al., "High Frequency of BCL-6 Mutations and Consistent Expression of the Transcription Factors OCT-2, BOB-1, and PU.1 in the Absence of Immunoglobulins", Amer. J. Path., Vol. 162(1), pp. 243-253 (2003)
RE	SAG	Pittaluga, et al., "BCL-6 Expression in Reactive Lymphoid Tissue and in B-Cell Non-Hodgkins Lymphomas", J. Pathol., Vol. 179, pp. 145-150 (1996)
RE	SAH	Rack, et al., "Translocation of BCL2 and BCL6 to the same immunoglobulin heavy chain locus in a case of Follicular Lymphoma", Leuk. Lymphoma, Vol. 46(10), pp. 1513-1516 (2005)
RE	SAI	Reichardt, et al., "Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor", EMBO J., Vol. 20(24), pp. 7168-7123 (2001)
RE	SAJ	Roumier, et al., "FISH analysis with a YAC probe improves detection of LAZ3/BCL6 rearrangement in non-Hodgkin's lymphoma", Hematol. J., Vol. 1, pp. 117-125 (2000)
RE	SAK	Shen, et al., "Mutation of BCL-6 Gene in Normal B Cells by the Process of Somatic Hypermutation of Ig Genes", Science, Vol. 280, pp. 1750-1752 (1998)
RE	SAL	Shvarts, et al., "A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19 <sup>ARF</sup> -p53 signaling", Genes Develop., Vol. 16, pp. 681-686 (2002)
RE	SAM	Sidransky, et al., "Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples", Science, Vol. 252, pp. 706-709 (1991)
RE	SAN	Tokuohisa, Takeshi, "A role for Bc16 in immune memory development", Vol. 47(16), pp. 2306-2312 (2002)

EXAMINER

Takeshi

DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

6AA	Ueda, et al., "Non-immunoglobulin/BCL6 Gene Fusion in Diffuse Large B-cell Lymphoma: Prognostic Implications", Leukemia Lymphoma, Vol. 43(7), pp. 1375-1381 (2002)
6AB	Vasanwala, et al., "Repression of AP-1 Function: A Mechanism for the Regulation of Blimp-1 Expression and B Lymphocyte Differentiation by the B Cell Lymphoma-6 Protooncogene", J. Immunol., Vol. 169, pp. 1922-1929 (2002)
6AC	Wang, et al., "Stat1 as a Component of Tumor Necrosis Factor Alpha Receptor 1-TRADD Signaling Complex to Inhibit NF- $\kappa$ B Activation", Molec. Cell. Biol., Vol. 20(13), pp. 4505-4512 (2000)
6AD	Wlodarska, et al., "Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma", Blood, Vol. 101(2), pp. 706-710 (2003)
6AE	Wong, et al., "Components of the SMRT Corepressor Complex Exhibit Distinctive Interactions with the POZ Domain Oncoproteins PLZF, PLZF-RAR $\alpha$ , and BCL-6", J. Biol. Chem., Vol. 273(42), pp. 27695-27702 (1998)
6AF	Ye, et al., "The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation", Nature Genetics, Vol. 16, pp. 161-170 (1997)
6AG	Ye, et al., "Alterations of a Zinc Finger-Encoding Gene, BCL-6, in Diffuse Large-Cell Lymphoma", Science, Vol. 262, pp. 747-750 (1993)
6AH	Zhang, et al., "A Putative Exonic Splicing Polymorphism in the BCL6 Gene and the Risk of Non-Hodgkin Lymphoma", J. National Cancer Institute, Vol. 97(21), pp. 1616-1618 (2005)
6AI	Zhou, et al., "Transcriptional Regulation of the BCL-6 Gene: Mechanistic Dissection Using Mutant Cell Lines", Molec. Medicine, Vol. 8(10), pp. 645-654 (2002)
6AJ	NCBI Entrez Accession No. AB018337 (gi:3882308), Nagase, et al., June 16, 1999
6AK	NCBI Entrez Accession No. AB056421 (gi:13358931), Osada, et al., March 1, 2005
6AL	NCBI Entrez Accession No. L29219 (gi:632963), Johnson, et al., January 24, 1995
6AM	NCBI Entrez Accession No. NM_001706 (gi:21040323), Zhang, et al., December 4, 2005
6AN	NCBI Entrez Accession No. NM_005500 (gi:4885584), Lois, et al., October 16, 2005

EXAMINER

R. Lonski

DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group 1653

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

7AA	NCBI Entrez Accession No. NM_016323 (gi:7705930), Hochrainer, et al., October 23, 2005
7AB	NCBI Entrez Accession No. NM_022136 (gi:48762708), Zhu, et al., October 18, 2005
7AC	NCBI Entrez Accession No. NM_145169 (gi:21553316), Director MGC Project., September 24, 2005
7AD	
7AE	
7AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

M. Gleason

DATE CONSIDERED

4/18/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.